Antiepidermal Growth Factor Receptor Monoclonal Antibodies : Applications in Colorectal Cancer

Abstract EN

Patients with metastatic colorectal cancer have a poor prognosis and present a challenge to clinicians.

The role of the antiepidermal growth factor receptor (EGFR) pathway in tumorogenesis and tumor progression has been well defined.

This paper will review the use of anti-EGFR monoclonal antibodies in the treatment of operable, as well as metastatic colorectal cancer both in the setting of KRAS mutation unselected patients and later in KRAS wild-type patients.

Active investigations designed to further identify predictive biomarkers that may be potentially druggable are reviewed as well.